Analysis: New Call for FDA Openness
March 07, 2007 | The call comes at a time when the agency is facing a barrage of criticism about how it handled several drugs, including Vioxx and anti-depressants. The momentum to change the policy of business as usual at the FDA has been intensified by recent negative reports from the Institute of Medicine and the Government Accountability Office and the Democrats in Congress, who have tightened oversight of the agency. Story in UPI.
Feeds